Table 5.
Adverse events in 83 patients with stable or recurrent malignant glioma who received erlotinib alone or combined with temozolomide
|
Severity (No. of Patients) |
|||||
|---|---|---|---|---|---|
| Adverse Event | No. of Patients (%) | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
| Rash | 70 (84) | 28 | 31 | 11 | 0 |
| Fatigue | 55 (67) | 17 | 34 | 4 | 0 |
| Diarrhea | 53 (64) | 36 | 14 | 3 | 0 |
| White blood count | 33 (40) | 20 | 11 | 2 | 0 |
| Headache | 29 (35) | 22 | 6 | 1 | 0 |
| Liver dysfunction | 26 (32) | 21 | 4 | 1 | 0 |
| Constipation | 24 (29) | 14 | 10 | 0 | 0 |
| Nausea/vomiting | 21 (26) | 9 | 10 | 2 | 0 |
| Dry mouth | 20 (24) | 20 | 0 | 0 | 0 |
| Platelet count | 13 (16) | 3 | 0 | 4 | 6 |
| Pruritis | 10 (12) | 6 | 4 | 0 | 0 |
| Infections | 9 (11) | 1 | 7 | 0 | 1* |
| Kidney dysfunction | 8 (10) | 6 | 1 | 1 | 0 |
| Other eye (NOS) | 6 (7) | 5 | 1 | 0 | 0 |
| Fever | 6 (7) | 4 | 2 | 0 | 0 |
| Photophobia | 4 (5) | 3 | 1 | 0 | 0 |
| Blurred vision | 4 (5) | 2 | 2 | 0 | 0 |
| Decreased vision | 2 (2) | 2 | 0 | 0 | 0 |
| Stomatitis | 1 (1) | 1 | 0 | 0 | 0 |
| Back pain | 1 (1) | 1 | 0 | 0 | 0 |
Abbreviation: NOS, not otherwise specified.
*
Grade 5.